Callan Family Office, LLC Ligand Pharmaceuticals Inc Transaction History
Callan Family Office, LLC
- $3.14 Trillion
- Q3 2025
A detailed history of Callan Family Office, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Callan Family Office, LLC holds 2,865 shares of LGND stock, worth $575,463. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,865
Previous 2,864
0.03%
Holding current value
$575,463
Previous $326 Million
55.88%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding LGND
# of Institutions
348Shares Held
20.3MCall Options Held
19KPut Options Held
11.5K-
Black Rock Inc. New York, NY2.87MShares$577 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.08MShares$417 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.04MShares$209 Million0.09% of portfolio
-
Macquarie Group LTD Australia, C3752KShares$151 Million0.16% of portfolio
-
State Street Corp Boston, MA749KShares$151 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $3.39B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...